Boston Scientific's Off-Label Stent Sales Probed

Law360, New York (February 28, 2008, 12:00 AM EST) -- Boston Scientific Corp.'s annual report to the U.S. Securities and Exchange Commission said Thursday that the Department of Justice is investigating allegations that the company promoted its biliary stents for off-label uses.

Off-label use refers to the application of a product in a way not officially approved by the U.S. Food and Drug Administration. Doctors are free to prescribe off-label uses, but manufacturers cannot promote them.

The Massachusetts-based maker of medical devices reported in its 10K filing for fiscal 2007 that the Department of Justice contacted...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.